Zimmer Biomet Jumps 15% to 52-Week High on Q3 Beat and Raised Guidance
ZBH sits 41% above its 52-week low of $79.12.
Summary
Zimmer Biomet beat on both lines: adjusted EPS of $1.90 versus $1.88 expected and sales of $2.063 billion versus $2.040 billion, up 3.1% reported and 3.7% constant currency. The stock is up 14.98% at $111.60, a new 52-week high. Hips grew 7% globally, SET 7.1%, and technology/data, bone cement and surgical 13%, with tech and data up over 30% in the U.S.; knees remain the drag, and management expects near-term pressure to persist. The company raised FY2026 adjusted EPS guidance to $8.50-$8.60 from $8.47-$8.59, narrowed sales to $8.594-$8.635 billion, and lifted organic constant currency growth to 3%-3.5% from 2.25%-3.25%. The guidance raise on a challenged knee franchise is the real story — it tells you hips and robotics are carrying the P&L.
At the time of this announcement, ZBH was trading at $111.76 on NYSE in the Life Sciences sector, with a market capitalization of approximately $21.3B. The 52-week trading range was $79.12 to $112.55. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Benzinga.